

# Microfluidics: Advancements in Point-Of-Care Testing

**Zikayo Amulaga R.**

**Faculty of Medicine Kampala International University Uganda**

## **ABSTRACT**

Microfluidics, a technology that manipulates fluids at micrometer scales, has emerged as a transformative tool in healthcare, particularly in point-of-care (POC) testing. The integration of microfluidic systems has enabled rapid diagnostics, minimal sample requirements, and high-throughput testing, providing significant improvements in clinical outcomes. This review highlights the foundational principles of microfluidics, advancements in fabrication techniques such as 3D printing, and their applications in detecting and managing infectious and chronic diseases. Despite its promise, the widespread adoption of microfluidic-based POC devices faces challenges, including scalability, cost-effectiveness, and regulatory hurdles. Future directions suggest potential breakthroughs in personalized medicine, digital health, and hybrid diagnostic platforms. Microfluidics remains a promising technology to bridge healthcare gaps globally, particularly in resource-constrained settings.

**Keywords:** Microfluidics, point-of-care testing, lab-on-a-chip, diagnostics, fabrication techniques, 3D printing.

## **INTRODUCTION**

The recent development of man-made micro- and nanometer-sized manipulators has given researchers powerful tools to control and investigate biological systems on the cellular and molecular levels. The fabrication of microdevices is now standard in chemical and physical technology. Materials, procedures, and components have been developed that allow efficient manipulation and analysis of picoliter or nanoliter volumes at speeds of approximately 1–100 centimeters per second. This area is called microfluidics because it deals with volumes and flow rates of fluid many orders of magnitude smaller than typical applications of fluid mechanics. The ten-year historical review shows the trends. As technical tools, microfluidic devices can focus reactions and reagents in time and space, achieve high throughput and uniform chemical kinetics, manipulate cells and molecules in complex ways using simple and integrated control, measure changes in cellular function at high information content using small numbers of cells or molecules, and serve as compact portable devices [1, 2]. The scientific and medical literature and the worldwide patent literature are full of devices and methods that are based on microfluidic technologies. This huge activity focuses on biological sensors, DNA and protein diagnostics, cell structure and function, the flow of blood, and other parameters to assist doctors and health workers in their clinical decisions. However, the number of publications and patents that demonstrate a novel microfluidic principle is relatively few. The innovations are in the combination and application of microfluidic technologies, which have firmly established foundations. There is now a plethora of commercial microfluidic chips and instruments that provide platforms for different applications. The applications of micro-total analysis systems are where sample processing, chemical transformations, and detection are fixed physically to the chip. These systems serve as tabletop analytical devices in the laboratory or field and are used in applications demanding highly integrated, fast, and reproducible analysis as in genomics, proteomics, and early diagnostics [3, 4].

### Principles and Technologies in Microfluidics

Sprawling over a wide range of scientific and engineering disciplines, microfluidics is concerned with the behavior and manipulation of fluids at micrometer scales. Although microfluidic devices function under a variety of principles, such as fluid dynamics, chemical interactions between fluid and surface, surface tension, or electrokinetics, in this chapter we focus on devices operating based on the principles of fluid dynamics. These are also commonly known as 'lab-on-a-chip' systems. Additionally, microvalves have been utilized in controlling the flow in micro-TAS (Total Analysis System). The development of micropumps has also been discussed [5, 6]. The advancement of microfluidics has substantially benefited from the development of novel fabrication techniques. Initially, devices were manufactured with photolithography, commonly used in the semiconductor industry, and were made of rigid polymers such as poly(dimethylsiloxane) and polymethylmethacrylate. Poly(dimethylsiloxane) is achieved by the soft lithography technique. Device fabrication was subsequently expanded to include alternative materials such as glass, ceramics, and more recently, polymers. Fabrication is also possible by utilizing computer-controlled tabletop drilling machines to pattern thin adhesive sheets wrapping two glass slides, or 3D printers for manufacturing hybrid devices. The introduction of 3D printing and rapid prototyping for microfluidic device fabrication is an important innovation in the microfluidics field. In addition to revolutionizing the process of device design and fabrication, the use of 3D prints has raised questions about whether 3D prints are biocompatible and whether the standard protocols for designing and printing devices should be modified. Consequently, this innovation is a growing subfield in the microfluidics literature. These fabrication techniques permit the development of increasingly complex devices. In the field of microfluidics, it is also crucial to decide on appropriate materials due to their fundamental properties. Biocompatibility is the most important aspect of material selection for biological applications [7, 8]. Two types of micropumps are operated: passive and active. Passive pumping employs changes in pressure, surface energy, and vapor pressure, then capillary action assists fluid transport. On the other hand, active pumping is carried out by a motor and can control the movement of fluids independent of other variables. While passive pumping does not require external energy, it is slower and also more sensitive to fluctuations in the surrounding environment. Miniaturization effectively makes chemical and physical reactions and analysis faster because it reduces the distance reactive components need to travel. Moreover, miniaturization increases the total specific surface-to-volume ratio, thus improving the signal-to-noise ratios of external measurements. Integration allows different processes to be performed one after another or simultaneously. Both these separate or interconnected processes occur within microfluidic structures, also known as chips. Integrating reactions confers other advantages, like minimizing dispersion and increasing efficiency. Integrated systems have greater reliability and precision compared to their macroscopic counterparts because they eliminate the connections that exist in traditional systems [9, 10].

### Applications of Microfluidics in Point-Of-Care Testing

Microfluidics is a rapidly growing field with a multitude of practical applications, particularly within point-of-care testing. This review aims to discuss the on-ground applications of microfluidics and highlight the complexity of these technologies. When microfluidic systems are designed with the intention of carrying out biochemical tests, they have the ability to produce rapid diagnostics with a small volume of samples. In the context of point-of-care testing, microfluidic systems can assist in providing more accurate results faster than ever before, improving the outcome for patients who require treatment. Throughout this review, real-life examples and case studies have been used to emphasize the actual applications of these microfluidic devices. The applications discussed emphasize the potential of microfluidic systems in a variety of settings, moving from aiding clinicians in making rapid diagnoses to providing crucial information to patients themselves. "Real applications" of microfluidics have been divided into two categories: (a) detecting, with multiple examples described, and (b) managing, with particular focus placed on chronic diseases. Overarching examples of detecting diseases have been further divided into detecting infectious diseases and chronic diseases. Finally, the complexity of managing diseases has been illustrated by these real-life case studies. Providing "real" case studies is necessary and enhances this text, as well as both the complexity and usefulness of these technologies used in point-of-care testing. The in-depth discussion of a wide range of applications serves to underscore the broad utility of microfluidics—aiding clinicians in diagnosing and treating patients—on a global scale [11, 12].

### Challenges and Future Directions

While microfluidics provides a promising platform for healthcare, especially in providing bedside diagnostics, there are various barriers that have hampered the advancement of microfluidics into a paradigm-changing technology. The commercial acceptance of microfluidic-based devices and point-of-care assays depends on the practicability and cost factors as well. The integration of microfluidic devices into complex circuits cannot be manufactured at scale, and regulatory hurdles in pattern approvals and clinical verifications are also barriers to microfluidic devices. The sensitivity of paper-based microfluidic devices has been reported to show lot-to-lot variation and less sensitivity in some paper devices. Other limitations in paper microfluidic devices include rapid dissipation of signal and errors in results due to technical problems. The efficient processing of whole blood is a hurdle in field operability. Sensitive equipment with dedicated accessories is vital, requiring exact functionality without technical snags for whole blood clinician samples. Practical execution of point-of-care assays should not influence the performance of the test or the analyst operating the assays. Besides technical requirements, affordability and user acceptance are stringent factors that should be critically addressed for the commercialization of microfluidic devices. Currently, microfluidic devices are not as popular as other molecular point-of-care testing technologies and are not cost-effective. Quicker commercialization is difficult for microfluidic devices. New technological platforms involve comparatively similar investigations on mass flow sensors and analytical signal processing for detection. The public market should mature for microfluidic devices. The hybrid use of microfluidics and other promising technologies could add a new dimension to this field of technology. The future attractiveness of this technology includes personalized medicine, liquid biopsy, and intersections of digital health. The advancement of solid-state materials having low effects would be an essential contribution, as the detection signal depends directly on the aerosol-based effects formed in flow-through techniques. Communities trying to use microfluidics point-of-care testing methods often face challenging circumstances and high ambient conditions, which could lead to the development of an attractive mixed signal processing system that could eliminate electrical noise associated with such harsh existing operational conditions. Long-term biological signal processing with a lesser threshold value suitable for bio-microchip technologies could enhance this domain. Personalized digital health services could also be developed with a cloud computing mechanism [13, 14].

### Implications For Healthcare

Microfluidics has the potential to considerably advance the current practice of point-of-care testing. It can provide a way to integrate the process of sampling, processing, and signal detection in a way that is not currently possible. The minimization of manual processing steps makes the test less subjective, which could reduce errors and help to improve patient outcomes. Reducing the time between blood collection and results could facilitate the timely initiation of the most appropriate treatment; this is particularly important for people presenting to hospitals during public health emergencies [15, 16]. Ongoing laboratory research is needed to show that the devices are sensitive and specific enough to detect the target infections or antibodies and to confirm that they are cost-effective for meeting the particular health need. It is also important to consider the integration of these technologies into existing primary healthcare systems. Throughout this process, researchers may need to engage with decision-makers, clinicians, and industry to facilitate the adoption of the new test in any given healthcare setting [17, 18]. Microfluidic technologies have shown promise for point-of-care testing across a range of healthcare settings. Recent technological advancements are beginning to overcome many of the reported barriers and limitations of current testing systems. Technologies are beginning to show potential for use in resource-limited settings, but continued multidisciplinary research will be vital in order to address the limitations identified and to help ensure successful global implementation [19, 20].

### CONCLUSION

Microfluidic technologies hold immense potential to revolutionize point-of-care testing, offering rapid, reliable, and minimally invasive diagnostic solutions. Their ability to integrate sampling, processing, and signal detection into compact systems has profound implications for improving healthcare delivery. Despite existing barriers, ongoing research and technological advancements are addressing issues related to scalability, affordability, and user adoption. Future innovations, particularly in personalized medicine and digital health, may further enhance the role of microfluidics in global healthcare. For successful implementation, multidisciplinary collaboration between researchers, clinicians, and policymakers will be critical. As the field evolves, microfluidics is poised to become a cornerstone of accessible and effective diagnostics worldwide.

## REFERENCES

1. Aubry G, Lee HJ, Lu H. Advances in microfluidics: technical innovations and applications in diagnostics and therapeutics. *Analytical Chemistry*. 2023 Jan 10;95(1):444-67.
2. Huang B, Ge X, Rubinstein BY, Chen X, Wang L, Xie H, Leshansky AM, Li Z. Gas-assisted microfluidic step-emulsification for generating micron-and submicron-sized droplets. *Microsystems & Nanoengineering*. 2023 Jul 10;9(1):86. [nature.com](#)
3. Cai Y, Li Z, Sun C, Zhao X, Wu S, Huang G, Tang S, Dai P, Wei X, You H. A centrifugal-driven spiral microchannel microfiltration chip for emulsion and deformable particle sorting. *Lab on a Chip*. 2024;24(15):3738-51. [\[HTML\]](#)
4. Wang D, Jin K, Ji J, Hu C, Du M, Belgaid Y, Shi S, Li J, Hu S, Nathan A, Yu J. Active-matrix digital microfluidics design for field programmable high-throughput digitalized liquid handling. *Iscience*. 2024 May 17;27(5). [cell.com](#)
5. Gharib G, Bütün İ, Muganlı Z, Kozalak G, Namlı İ, Sarraf SS, Ahmadi VE, Toyran E, Van Wijnen AJ, Koşar A. Biomedical applications of microfluidic devices: a review. *Biosensors*. 2022 Nov 16;12(11):1023. [mdpi.com](#)
6. Nasiri R, Shamloo A, Ahadian S, Amirifar L, Akbari J, Goudie MJ, Lee K, Ashammakhi N, Dokmeci MR, Di Carlo D, Khademhosseini A. Microfluidic-based approaches in targeted cell/particle separation based on physical properties: fundamentals and applications. *Small*. 2020 Jul;16(29):2000171. [\[HTML\]](#)
7. Glasco DL, Sheelam A, Ho NH, Mamaril AM, King M, Bell JG. Editors' Choice—Review—3D printing: an innovative trend in analytical sensing. *ECS Sensors Plus*. 2022 Apr 7;1(1):010602. [iop.org](#)
8. Lodhi SK, Gill AY, Hussain I. 3D Printing Techniques: Transforming Manufacturing with Precision and Sustainability. *International Journal of Multidisciplinary Sciences and Arts*. 2024 Aug 21;3(3):129-38. [itscience.org](#)
9. Medina DA, Cardoso AT, Maciel EV, Lanças FM. Current materials for miniaturized sample preparation: recent advances and future trends. *TrAC Trends in Analytical Chemistry*. 2023 Aug 1;165:117120. [\[HTML\]](#)
10. Lopes LC, Santos A, Bueno PR. An outlook on electrochemical approaches for molecular diagnostics assays and discussions on the limitations of miniaturized technologies for point-of-care devices. *Sensors and Actuators Reports*. 2022 Nov 1;4:100087.
11. Venkatesalu S, Dilliyappan S, Kumar AS, Palaniyandi T, Baskar G, Ravi M, Sivaji A. Prospectives and retrospectives of microfluidics devices and lab-on-A-chip emphasis on cancer. *Clinica Chimica Acta*. 2024 Jan 1;552:117646. [\[HTML\]](#)
12. Noviana E, Ozer T, Carrell CS, Link JS, McMahon C, Jang I, Henry CS. Microfluidic paper-based analytical devices: from design to applications. *Chemical reviews*. 2021 Jun 14;121(19):11835-85. [\[HTML\]](#)
13. Xie Y, Dai L, Yang Y. Microfluidic technology and its application in the point-of-care testing field. *Biosensors and Bioelectronics: X*. 2022 May 1;10:100109.
14. Wang C, Liu M, Wang Z, Li S, Deng Y, He N. Point-of-care diagnostics for infectious diseases: From methods to devices. *Nano Today*. 2021 Apr 1;37:101092.
15. Sachdeva S, Davis RW, Saha AK. Microfluidic point-of-care testing: commercial landscape and future directions. *Frontiers in Bioengineering and Biotechnology*. 2021 Jan 15;8:602659. [frontiersin.org](#)
16. Yang SM, Lv S, Zhang W, Cui Y. Microfluidic point-of-care (POC) devices in early diagnosis: A review of opportunities and challenges. *Sensors*. 2022 Feb 18;22(4):1620.
17. Chen W, Khurshid S, Singer DE, Atlas SJ, Ashburner JM, Ellinor PT, McManus DD, Lubitz SA, Chhatwal J. Cost-effectiveness of screening for atrial fibrillation using wearable devices. In *JAMA Health Forum* 2022 Aug 5 (Vol. 3, No. 8, pp. e222419-e222419). American Medical Association. [jamanetwork.com](#)
18. Romero CP, Marinho DS, Castro R, de Aguiar Pereira CC, Silva E, Caetano R, Elias FT, Chilcott J, Dixon S. Cost-effectiveness analysis of point-of-care rapid testing versus laboratory-based testing for antenatal screening of syphilis in Brazil. *Value in Health Regional Issues*. 2020 Dec 1;23:61-9. [sciencedirect.com](#)

19. Gurkan UA, Wood DK, Carranza D, Herbertson LH, Diamond SL, Du E, Guha S, Di Paola J, Hines PC, Papautsky I, Shevkoplyas SS. Next generation microfluidics: fulfilling the promise of lab-on-a-chip technologies. Lab on a Chip. 2024;24(7):1867-74. [rsc.org](#)
20. Doganay MT, Chakraborty P, Bommakanti SM, Jammalamadaka S, Battalapalli D, Madabhushi A, Draz MS. Artificial intelligence performance in testing microfluidics for point-of-care. Lab on a Chip. 2024;24(21):4998-5008. [rsc.org](#)

**CITE AS: Zikayo Amulaga R. (2025). Microfluidics: Advancements in Point-Of-Care Testing. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 7(1):121-125**